NCT04073537

Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer

A Randomized, Double-Blind, Multicenter, Phase Ⅲ Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 386 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor-associated kinases involved in cell proliferation such as PDGFRα/β, c-Kit, and Ret have significant inhibitory activities.

Conditions

• Squamous Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Anlotinib	A multi-target receptor tyrosine kinase inhibitor.
DRUG	Placebos	Anlotinib blank analog capsule.
DRUG	Paclitaxel	Paclitaxel 175 mg/m\^2 IV on Day 1 of each 21-day cycle.
DRUG	Carboplatin	Carboplatin area under the concentration curve (AUC) 5 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.

Timeline

• Start date: 2019-10-31
• Primary completion: 2021-07-31
• Completion: 2022-06-30
• First posted: 2019-08-29
• Last updated: 2019-08-29

Locations

2 sites across 1 country: China